QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.106.106989v1 320/1/486    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Marquis, K. L. Articles by Rosenzweig-Lipson, S. Search for Related Content PubMed PubMed Citation Articles by Marquis, K. L. Articles by Rosenzweig-Lipson, S.

BEHAVIORAL PHARMACOLOGY

WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-Octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A Novel 5-Hydroxytryptamine 2C Receptor-Selective Agonist with Preclinical Antipsychotic-Like Activity

Discovery Neuroscience (K.L.M., S.F.L., J.A.B., M.J.P., T.A.C., S.M.G., H.Q.N., L.A.D., J.E.B., S.R.-L.) and Chemical and Screening Sciences (A.L.S., G.S., B.L.H.), Wyeth Research, Princeton, New Jersey; St. John's University, Jamaica, New York (C.R.A.); and Vanderbilt University, Nashville, Tennessee (H.Y.M.)

Serotonin-2C (5-HT_2C) receptor antagonists and agonists have been shown to affect dopamine (DA) neurotransmission, with agonists selectively decreasing mesolimbic DA. As antipsychotic efficacy is proposed to be associated with decreased mesolimbic DA neurotransmission by virtue of DA D₂ receptor antagonism, the 5-HT_2C-selective receptor agonist, WAY-163909 [(7bR,10aR)-1,2, 3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7, 1hi]indole], was evaluated in animal models of schizophrenia and in vivo microdialysis and electrophysiology to determine the effects on mesolimbic and nigrostriatal DA neurotransmission. Similar to clozapine, WAY-163909 (1.7–30 mg/kg i.p.) decreased apomorphine-induced climbing with little effect on stereotypy and no significant induction of catalepsy. WAY-163909 (0.3–3 mg/kg s.c.) more potently reduced phencyclidine-induced locomotor activity compared with d-amphetamine with no effect on spontaneous activity. WAY-163909 (1.7–17 mg/kg i.p.) reversed MK-801 (5H-dibenzo[a,d]cyclohepten-5,10-imine (dizocilpine maleate)- and DOI [1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane]-disrupted prepulse inhibition of startle (PPI) and improved PPI in DBA/2N mice. In conditioned avoidance responding, WAY-163909 (0.3–3 mg/kg i.p.; 1–17 mg/kg p.o.) reduced avoidance responding, an effect blocked by the 5-HT_2B/2C receptor antagonist SB 206553 [5-methyl-1-(3-pyridylcarbamoyl)-1,2,3,5-tetrahydropyrrolo[2,3-f]indole]. WAY-163909 (10 mg/kg s.c.) selectively decreased extracellular levels of DA in the nucleus accumbens without affecting the striatum. Likewise, in vivo electrophysiological recordings showed a decrease in the number of spontaneously firing DA neurons in the ventral tegmental area but not in the substantia nigra with both acute and chronic (21-day) administration of WAY-163909 (1–10 mg/kg i.p.). Thus, the profile of the 5-HT_2C selective receptor agonist WAY-163909 is similar to that of an atypical antipsychotic and additionally may have rapid onset properties.

Address correspondence to: Dr. Karen L. Marquis, Discovery Neuroscience, Wyeth Research, CN 8000, Princeton, NJ 08543. E-mail: marquik{at}wyeth.com

This article has been cited by other articles:

				A. I. Abbas, P. N. Yadav, W.-D. Yao, M. I. Arbuckle, S. G. N. Grant, M. G. Caron, and B. L. Roth PSD-95 Is Essential for Hallucinogen and Atypical Antipsychotic Drug Actions at Serotonin Receptors J. Neurosci., June 3, 2009; 29(22): 7124 - 7136. [Abstract] [Full Text] [PDF]

				J. Dunlop, T. Lock, B. Jow, F. Sitzia, S. Grauer, F. Jow, A. Kramer, M. R. Bowlby, A. Randall, D. Kowal, et al. Old and New Pharmacology: Positive Allosteric Modulation of the {alpha}7 Nicotinic Acetylcholine Receptor by the 5-Hydroxytryptamine2B/C Receptor Antagonist SB-206553 (3,5-Dihydro-5-methyl-N-3-pyridinylbenzo[1,2-b:4,5-b']di pyrrole-1(2H)-carboxamide) J. Pharmacol. Exp. Ther., March 1, 2009; 328(3): 766 - 776. [Abstract] [Full Text] [PDF]

				F. Liu, S. Grauer, C. Kelley, R. Navarra, R. Graf, G. Zhang, P. J. Atkinson, M. Popiolek, C. Wantuch, X. Khawaja, et al. ADX47273 [S-(4-Fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: A Novel Metabotropic Glutamate Receptor 5-Selective Positive Allosteric Modulator with Preclinical Antipsychotic-Like and Procognitive Activities J. Pharmacol. Exp. Ther., December 1, 2008; 327(3): 827 - 839. [Abstract] [Full Text] [PDF]

				L. R. Gardell, K. E. Vanover, L. Pounds, R. W. Johnson, R. Barido, G. T. Anderson, I. Veinbergs, A. Dyssegaard, P. Brunmark, A. Tabatabaei, et al. ACP-103, a 5-Hydroxytryptamine 2A Receptor Inverse Agonist, Improves the Antipsychotic Efficacy and Side-Effect Profile of Haloperidol and Risperidone in Experimental Models J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 862 - 870. [Abstract] [Full Text] [PDF]